Hit enter to search or ESC to close

Press Releases

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

Alterity to Present at Life Sciences Investor Forum

Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy

Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

Appendix 4C – Q3 FY22 Quarterly Cash Flow Report

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting

Alterity Therapeutics to Participate in the Sachs Associates 5th Annual Neuroscience Innovation Forum

WEBCAST LINK: 34th Annual Roth Conference

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease

Appendix 4C – Q2 FY22 Quarterly Cash Flow Report

WEBCAST LINK: H.C. Wainwright BIOCONNECT Virtual Conference

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’s and Alzheimer’s

Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics to Participate in Two Upcoming Investor Conferences

AGM 2021 Presentation

Chairman’s Address 2021 Annual General Meeting

Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021

Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases

Appendix 4C – Q1 FY22 Quarterly Cash Flow Report

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

Presentation of New Biomarker Data at Scientific Congress

XBRL 30 June 2021 filed with the SEC

Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s

Quarterly Cash Flow Report

New Publication Demonstrates ATH434 is Neuroprotective

Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer’s and Parkinson’s

European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

Alterity Therapeutics to Present at the MST Access Australian Micro & Small Caps Conference

Quarterly Cash Flow Report

ATH434 protects brain cells and improves motor function

Alterity CEO David Stamler presents to US investors at the HC Wainwright Global Life Science Conference

Alterity to present at the 7th International Congress of Multiple System Atrophy

Alterity Half Year Results and Investor Webcast Notification

Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson’s disease clinical trials

Quarterly Cash Flow Report

New hope in global fight against antibiotic resistant superbugs

Alterity participates in world’s largest virtual healthcare conference JP Morgan

Dr David Stamler appointed CEO

Alterity and UniQuest to reverse bacterial resistance to antibiotics

Alterity presents at Finance News Network investor event

AGM 2020 Presentation

Chairman’s Address to Shareholders 2020 Annual General Meeting

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

Alterity completes Placement Tranche 1 raising $10M

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.

XBRL 30 June 2020 filed with the SEC

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

Alterity receives a $4.8 million R&D Tax Incentive Refund

European Commission approves Orphan Designation for Alterity’s lead drug candidate

Chairman’s Address to Shareholders 2019 Annual General Meeting

AGM 2019 Presentation

Alterity AGM Investor Conference Call

Alterity’s lead drug candidate receives positive opinion from European medical agency

Quarterly Cash Flow Report

Alterity PBT434 Poster Presented at 2019 MDS Congress

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

Alterity Therapeutics to Present at the Janney Healthcare Conference in New York

XBRL 30 June 2019 filed with the SEC

Quarterly Cash Flow Report

Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial

Alterity Therapeutics’ Finance News Network Presentation

Alterity Therapeutics talks to Finance News Network

Alterity Therapeutics Presents to Finance News Network

Alterity in the news: Herald Sun

Alterity Therapeutics commences US investor meetings following positive clinical data

Alterity Therapeutics AAN Presentation 5 May 2019

Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting

Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting

Alterity Therapeutics Investor Presentation

Alterity Therapeutics Launches to Asian Investors

Change of Company Name

Completion of investment by Life Biosciences LLC and capital raising update

Results of General Meeting

Prana EGM and Conference Call Facility

Prana receives A$3.3 million R&D Tax Incentive

Notice of General Meeting 2019

Prana receives Orphan Designation for PBT434 for treatment of MSA

Dr David Stamler’s Biotech Showcase Presentation

Prana Presents at Biotech Showcase

Life Biosciences LLC leads strategic investment of up to A$44.5 million in Prana

Prana Biotechnology 2018 AGM Presentation

Prana AGM Investor Conference Call

Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA

Link to XBRL Interactive Data 30 June 2018

PBT434 data to be presented at the International Congress of Parkinson’s Disease and Movement Disorders

First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases

Prana Biotechnology Investor Presentation

Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases

Dr David Stamler China Investor & Partnering Symposium Webcast

Prana to Present at the B. Riley FBR China Healthcare Investment & Partnering Symposium in Hangzhou, China

PBT434 poster presented at the 6th International Multiple System Atrophy Conference

Dr David Stamler Biotech Showcase Presentation

Prana meeting with investors at world’s largest healthcare conference in San Francisco

Prana receives $3 million R&D Tax Incentive Refund

Annual General Meeting Presentation 2017

Prana AGM Investor Conference Call

Annual Report Filed on Form 20-F with SEC

Prana commences research collaboration with Takeda for the treatment of Parkinson’s disease gastrointestinal neuropathology

Prana’s PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development

Prana’s Anti-Parkinsonian compound PBT434 presented at 13th International Conference for Alzheimer’s & Parkinson’s Diseases

Prana Business Update

Prana AGM investor webcast details

Prana provides regulatory update for PBT2 for the treatment of Huntington disease

Prana receives $4.8 million R&D Tax Incentive Cash Refund

New data from Reach2HD trial presented at American Neurological Association Annual Meeting

Prana – ANA Abstract Submission NLP

ANA NLP Poster

Annual Report filed on Form 20-F with SEC

Prana Alzheimer’s disease data features at world leading conference

Abstract from Movement Disorders Conference

Prana’s Huntington Disease trial analysis to feature at global movement disorder conference

Prana receives $6.5 million R&D Tax Incentive Refund

Prana Presents at World Orphan Drug Congress

Prana Maintains NASDAQ Listing

AGM Presentation

Prana AGM Webcast Details

Preliminary Final Report (Appendix 4E)

Prana reports FY15 financial results

Prana Announces Safety Outcomes of Alzheimer’s IMAGINE Extension Trial

Prana receives $6.8 million R&D Tax Incentive Refund

European Commission Approves PBT2 Orphan Designation for Huntington’s Disease

EMA publishes minutes recommending Orphan Drug Designation for PBT2

PBT2 recommended for orphan designation in Europe

FDA End of Phase 2 Status Update

The Lancet Neurology publishes Prana’s Huntington’s Disease Trial

Prana’s Founding Scientist and CSA publishes landmark paper in Nature

Prana Biotechnology 2014 Annual Report

Prana receives FDA Orphan Drug Designation for PBT2 for Huntington Disease

Prana Alzheimer’s disease Development Plan Update

Video Interview: Professor Ira Shoulson

World leader in movement disorders Professor Ira Shoulson joins Prana board

Prana Biotechnology announces top line results of Phase 2 IMAGINE trial of PBT2 in Alzheimer’s disease

Prana’s Alzheimer’s Disease Treatment Strategy Validated by Independent Study

Prana Biotechnology Presents to US Investors at 34th Cowen Healthcare Conference

IMAGINE Phase 2 clinical trial Investor Conference call

HCW&Co publishes Prana Reach2HD trial report, results “beat expectations”

Prana Biotechnology Investor Presentation and Audio Recording – Phase 2 HD trial

Prana Announces Successful Phase 2 Results in Huntington Disease Trial

Prana Biotechnology REACH2HD Investor Conference Call

Prana commences US Investor Roadshow

Prana Provides Update on PBT2 Alzheimer’s Disease Extension trial

Prana completes PBT2 dosing in IMAGINE Alzheimer’s Disease clinical trial

Prana’s PBT2 features as a top 10 global neuroscience project

Prana Provides Update on IMAGINE Trial and Extension Trial for Alzheimer’s Disease

Prana’s PBT2 Reverses Memory Loss in Normal Aging

Prana Completes Phase 2 Huntington Disease Trial with PBT2

Prana Doses First Patient in PBT2 Alzheimer’s Extension Study

Prana prepares for next steps in the PBT2 development path to market and commercialization with key appointments strategy

Prana Provides Update on PBT2 Trials

Prana drug treatment PBT2 named one of Top Neuroscience Projects to Watch

Parkinson’s UK Awards £150,000 to Study Prana’s PBT434

FDA Approval to Commence Huntington’s Disease Clinical Trial Using Prana’s PBT2: Huntington Study Group appointed to coordinate the trial and start recruitment

Prana Comments on Nature Medicine, PNAS and Journal of Alzheimer’s Disease articles that highlight the Role of Metals in Neurological Diseases

Prana Doses First Patient in the “IMAGINE” Phase II Alzheimer’s Disease Trial

PLoS ONE Journal Publishes Mechanistic Model of Alzheimer’s Disease Endorsing Prana’s PBT2

Prana Enrolls First Patient in the “Reach2HD” Phase II Huntington Disease Trial

Prana Comments on Archives of Neurology Publication Which Highlights Critical Role of Brain Metals in Huntington Disease Progression: MGH team publishes data that supports the use of PBT2 in Huntington disease

Prana to Present at the UBS Australian Healthcare Conference in Sydney and the Australian Life Science Investment Showcase in New York

Prana’s PBT2 presented at the Huntington’s Disease Society of America National Convention: Prana’s ‘Reach2HD’ Phase II trial on track

ABC Radio Jon Faine Program features Prana IMAGINE trial for Alzheimer’s disease

Prana Provides Clinical Trials Update: Alzheimer’s and Huntington disease trials on track

Prana’s Parkinson’s drug meets Michael J. Fox Foundation development milestone – PBT434 advances through IND enabling studies

Prana Shows Significant Promise in the Fight Against Alzheimer’s Disease According to Experts at Celebration of Science Conference

Prana Receives Recommendation to Proceed with Alzheimer’s Clinical Trial from Data Safety Monitoring Board (DSMB)

Further Information – Prana’s PBT2 Clinical Trials Cited as Most Advanced in Addressing Neurodegeneration from the Metal Equilibrium Perspective

Prana Scientist to Participate in Webcast to Discuss Alzheimer’s Disease Therapeutics: Recent Setbacks and Emerging Technologies on Monday, October 1

Prana Announces A$6.0 Million Capital Raising

Prana Provides Huntington Disease Trial Update in conjunction with the Huntington Study Group Annual Conference

Prana to present at New York Academy of Science Symposium on November 29th

Prana Completes Recruitment in Alzheimer’s Trial

Metal Hypothesis for Alzheimer’s, Huntington and other Neurodegenerative Diseases Declared Promising Therapeutic Strategy by Scientists at New York Academy of Sciences Symposium

Journal of Huntington’s Disease Publishes Benefits of PBT2

Prana Completes Recruitment in Huntington Trial

Prana Announces that New York Academy of Sciences eBriefing available online

Prana to Present at Cowen & Company Health Care Conference on March 4th in Boston, MA

Prana Announces that PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation

Prana’s PBT434 Inhibits Accumulation of Parkinson’s protein and Subsequent Death of Brain Cells

Prana Details Data Showing that PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation

Prana Announces Successful A$7 million Capital Raising

Prana Provides Clinical Trials Update

Prana Announces RD Refund

Prana announces Share Purchase Plan Closed

Prana presents new benchmark test to assess Huntington’s Disease patients in clinical trials

PBT434 drug candidate shows potential as “next-generation” disease-modifying treatment in Parkinson’s Disease

Prana Receives Approval For 12-Month Open Label Extension Study In Alzheimer’s Disease

Professor Rudy Tanzi Appointed Prana’s Chief Scientific Advisor

Receive news from Alterity Therapeutics